Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): informing clinical practice for multidisciplinary teams in England. Issue 1 (30th June 2022)

• Record Type: Journal Article
• Authors: Reeves, Helen L; Reicher, John; Priona, Georgia; Manas, Derek M; Littler, Peter
• Is Part Of: Frontline gastroenterology. Volume 14:Issue 1(2023)
• Page Start: 45
• Page End: 51
• Publication Date: 2022-06-30
• Subjects: HEPATOCELLULAR CARCINOMA -- AUDIT -- RADIOTHERAPY -- CHEMOTHERAPY; Gastroenterology -- Periodicals; 616.33005
• DOI: 10.1136/flgastro-2022-102137
• Languages: English
• ISSNs: 2041-4137

Abstract

Abstract : Objective: Hepatocellular carcinoma (HCC) deaths are rising alarmingly. Many patients are unsuitable for available therapies. Poor response rates further hamper outcomes for those that are. Selective internal radiation therapy (SIRT) offers hope, although which patients benefit over standard approaches remains unclear. Design/method: As a quality/service improvement, we audited consecutive patients treated with SIRT (2015-2020) by the Newcastle upon Tyne Hospitals National Health Service Foundation Trust HCC multidisciplinary team . Indications, Barcelona clinic liver cancer (BCLC) stage, treatment response, subsequent therapies and survival at 30 September 2021 were assessed Results: Fifty-one patients received SIRT. Thirty-day mortality was zero. Three months partial response, stable disease and progressive disease on imaging were 50%, 22% and 28%, respectively. Overall median survival was 21 months. There were four subgroups: (1) BCLC-B: HCC>7 cm too large for transarterial chemoembolisation (TACE) alone (n=21); (2) BCLC-B: HCC progressed post TACE (n=7); (3) BCLC-C: HCC with any combination of large tumour burden, branch portal vein thrombosis, non-hepatitis C virus aetiology (n=16); (4) BCLC-C: sorafenib inappropriate (n=7). In group 1, 5/21 (23.8%) of patients were downstaged to resection, 33% received subsequent medical therapies and median survival was >40 months. In BCLC-B patients treated second line (group 2), median survival was 14.2 months. In BCLC–C, median survival was 20.2 months for group 3 and 4.2 months for group 4. Conclusion: SIRT outcomes for advanced HCC, often bridging patients with adverse predictive factors to subsequent surgery or medical therapies, were encouraging. A role after TACE or for BCLC-C patients requires further assessment.